×
About 2,199 results

ALLMedicine™ Factor X Center

Research & Reviews  1,067 results

Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A.
https://doi.org/10.1080/14740338.2021.1893303
Expert Opinion on Drug Safety; Wang CP, Young G et. al.

Feb 22nd, 2021 - Emicizumab is a bispecific humanized monoclonal antibody that improves hemostasis by bridging activated factor IX and factor X to substitute for the function of missing activated FVIII. It is an alternative to prophylaxis with factor VIII replacem...

Management of Factor X Deficiency for Vaginal Delivery in a Parturient: A Case Report.
https://doi.org/10.1213/XAA.0000000000001405
A&A Practice; Yen CB, Katz DJ

Feb 12th, 2021 - Factor X (FX) deficiency is a rare coagulopathy that may cause bleeding complications in parturients. The literature on rotational thromboelastometry (ROTEM; Instrumentation Laboratory, Bedford, MA) to guide factor repletion and neuraxial placemen...

Hammerhead ribozyme cleavage of apolipoprotein B mRNA generates a truncated protein.
https://doi.org/10.1074/jbc.274.34.24161
The Journal of Biological Chemistry; Wang JP, Enjoji M et. al.

Feb 9th, 2021 - The upstream coagulation enzymes are homologous trypsin-like serine proteases that typically function in enzyme-cofactor complexes, exemplified by coagulation factor VIIa (VIIa), which is allosterically activated upon binding to its cell surface r...

Peroxisomal Dysfunction and Oxidative Stress in Neurodegenerative Disease: A Bidirectio...
https://doi.org/10.1074/jbc.272.35.22037
Advances in Experimental Medicine and Biology; Fransen M, Revenco I et. al.

Jan 8th, 2021 - Human factor X is a two-chain, 58-kDa, vitamin K-dependent blood coagulation zymogen. The light chain of factor X consists of an NH2-terminal gamma-carboxyglutamic acid (Gla) domain, followed by a few helical hydrophobic residues and the two epide...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  1,083 results

Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A.
https://doi.org/10.1080/14740338.2021.1893303
Expert Opinion on Drug Safety; Wang CP, Young G et. al.

Feb 22nd, 2021 - Emicizumab is a bispecific humanized monoclonal antibody that improves hemostasis by bridging activated factor IX and factor X to substitute for the function of missing activated FVIII. It is an alternative to prophylaxis with factor VIII replacem...

Management of Factor X Deficiency for Vaginal Delivery in a Parturient: A Case Report.
https://doi.org/10.1213/XAA.0000000000001405
A&A Practice; Yen CB, Katz DJ

Feb 12th, 2021 - Factor X (FX) deficiency is a rare coagulopathy that may cause bleeding complications in parturients. The literature on rotational thromboelastometry (ROTEM; Instrumentation Laboratory, Bedford, MA) to guide factor repletion and neuraxial placemen...

Hammerhead ribozyme cleavage of apolipoprotein B mRNA generates a truncated protein.
https://doi.org/10.1074/jbc.274.34.24161
The Journal of Biological Chemistry; Wang JP, Enjoji M et. al.

Feb 9th, 2021 - The upstream coagulation enzymes are homologous trypsin-like serine proteases that typically function in enzyme-cofactor complexes, exemplified by coagulation factor VIIa (VIIa), which is allosterically activated upon binding to its cell surface r...

Peroxisomal Dysfunction and Oxidative Stress in Neurodegenerative Disease: A Bidirectio...
https://doi.org/10.1074/jbc.272.35.22037
Advances in Experimental Medicine and Biology; Fransen M, Revenco I et. al.

Jan 8th, 2021 - Human factor X is a two-chain, 58-kDa, vitamin K-dependent blood coagulation zymogen. The light chain of factor X consists of an NH2-terminal gamma-carboxyglutamic acid (Gla) domain, followed by a few helical hydrophobic residues and the two epide...

see more →

News  45 results

Health Canada approves emicizumab
https://www.mdedge.com/hematology-oncology/article/184793/thrombosis/health-canada-approves-emicizumab
HT Staff

Aug 8th, 2018 - Photo from Business Wire Emicizumab (Hemlibra) Health Canada has approved emicizumab (Hemlibra®) for use as routine prophylaxis to prevent or reduce bleeding episodes in hemophilia A patients with factor VIII inhibitors. Emicizumab is a bispecific.

Emicizumab granted priority review for hemophilia A without inhibitors
https://www.mdedge.com/hematology-oncology/article/184916/thrombosis/emicizumab-granted-priority-review-hemophilia-without-inhibitors
HT Staff

Jun 7th, 2018 - By Crystal (Crystl) from Bloomington, USA - Flickr Bleeding human finger The US Food and Drug Administration (FDA) has granted priority review for emicizumab (Hemlibra®) for adults and children with hemophilia A without factor VIII inhibitors. Ear.

Emicizumab receives breakthrough designation
https://www.mdedge.com/hematology-oncology/article/185010/thrombosis/emicizumab-receives-breakthrough-designation
HT Staff

Apr 18th, 2018 - Photo from Business Wire Emicizumab (Hemlibra) The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to emicizumab (Hemlibra®) for patients who have hemophilia A without factor VIII inhibitors. Emicizumab is a bisp.

Product approved for hemophilia patients in Japan
https://www.mdedge.com/hematology-oncology/article/185054/thrombosis/product-approved-hemophilia-patients-japan
HT Staff

Mar 27th, 2018 - Photo from Business Wire Emicizumab (Hemlibra) Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the bispecific factor IXa- and factor X-directed antibody emicizumab (Hemlibra), according to Chugai Pharmaceutical Co. , Ltd.

see more →